Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC

Launched by PARC DE SALUT MAR · Nov 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a type of blood test called ctDNA (circulating tumor DNA) to see how well it can help doctors monitor the effectiveness of treatments for patients with locally advanced lung cancer that cannot be surgically removed. The trial is focused on patients who are receiving a combination of radiation therapy and chemotherapy, with some also getting a drug called durvalumab to help boost their immune response. By tracking ctDNA levels, researchers hope to predict how well the treatments are working and if the cancer might come back after treatment.

To be eligible for this study, patients must be at least 18 years old and have a confirmed diagnosis of unresectable locally advanced lung cancer. It's important that they are willing to participate in follow-up evaluations to assess their response to therapy. If someone is interested in joining the trial, they can expect to have regular blood tests and possibly benefit from close monitoring of their condition. The trial is currently recruiting participants of all genders, and it aims to gather valuable information that could improve future treatments for lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed, histologically confirmed, unresectable locally advanced NSCLC.
• • ≥18 years of age.
• • Ability to understand the written informed consent and willingness to sign it.
• Exclusion Criteria:
• • Patients who are unwilling to follow-up evaluation of response to therapy.
• • Any condition that, in the opinion of the investigator, would interfere with study results.

Trial Officials